Citadel Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.16M | Sell |
16,400
-4,100
| -20% | -$544K | ﹤0.01% | 5923 |
|
|
2025
Q4 | $2.91M | Buy |
20,500
+8,000
| +64% | +$1.16M | ﹤0.01% | 5225 |
|
|
2025
Q3 | $1.75M | Sell |
12,500
-5,200
| -29% | -$705K | ﹤0.01% | 6340 |
|
|
2025
Q2 | $2.22M | Sell |
17,700
-10,600
| -37% | -$1.22M | ﹤0.01% | 5506 |
|
|
2025
Q1 | $3.13M | Buy |
28,300
+2,500
| +10% | +$317K | ﹤0.01% | 4689 |
|
|
2024
Q4 | $3.52M | Sell |
25,800
-21,700
| -46% | -$2.68M | ﹤0.01% | 4565 |
|
|
2024
Q3 | $5.47M | Buy |
47,500
+19,400
| +69% | +$2.66M | ﹤0.01% | 3795 |
|
|
2024
Q2 | $3.87M | Buy |
28,100
+13,900
| +98% | +$1.91M | ﹤0.01% | 4156 |
|
|
2024
Q1 | $1.96M | Buy |
14,200
+4,000
| +39% | +$546K | ﹤0.01% | 5563 |
|
|
2023
Q4 | $1.34M | Sell |
10,200
-20,900
| -67% | -$2.41M | ﹤0.01% | 6092 |
|
|
2023
Q3 | $3.5M | Buy |
31,100
+1,700
| +6% | +$179K | ﹤0.01% | 4221 |
|
|
2023
Q2 | $2.77M | Buy |
29,400
+19,700
| +203% | +$1.92M | ﹤0.01% | 4603 |
|
|
2023
Q1 | $982K | Buy |
9,700
+4,600
| +90% | +$479K | ﹤0.01% | 6823 |
|
|
2022
Q4 | $609K | Buy |
5,100
+100
| +2% | +$11.7K | ﹤0.01% | 7834 |
|
|
2022
Q3 | $531K | Sell |
5,000
-3,300
| -40% | -$335K | ﹤0.01% | 8328 |
|
|
2022
Q2 | $809K | Sell |
8,300
-73,200
| -90% | -$6.76M | ﹤0.01% | 7517 |
|
|
2022
Q1 | $7.64M | Buy |
81,500
+44,600
| +121% | +$3.78M | ﹤0.01% | 3401 |
|
|
2021
Q4 | $3.14M | Sell |
36,900
-2,200
| -6% | -$202K | ﹤0.01% | 5248 |
|
|
2021
Q3 | $3.75M | Sell |
39,100
-5,200
| -12% | -$491K | ﹤0.01% | 4882 |
|
|
2021
Q2 | $4.31M | Buy |
44,300
+15,400
| +53% | +$1.48M | ﹤0.01% | 4761 |
|
|
2021
Q1 | $2.81M | Sell |
28,900
-2,200
| -7% | -$231K | ﹤0.01% | 5595 |
|
|
2020
Q4 | $2.98M | Sell |
31,100
-14,400
| -32% | -$1.39M | ﹤0.01% | 4591 |
|
|
2020
Q3 | $4.38M | Sell |
45,500
-7,400
| -14% | -$856K | ﹤0.01% | 3348 |
|
|
2020
Q2 | $6.45M | Sell |
52,900
-500
| -0.9% | -$55.3K | ﹤0.01% | 2728 |
|
|
2020
Q1 | $4.62M | Sell |
53,400
-34,700
| -39% | -$3.4M | ﹤0.01% | 2834 |
|
|
2019
Q4 | $9.47M | Buy |
88,100
+33,600
| +62% | +$3.52M | ﹤0.01% | 2267 |
|
|
2019
Q3 | $4.91M | Sell |
54,500
-6,100
| -10% | -$570K | ﹤0.01% | 3136 |
|
|
2019
Q2 | $5.12M | Sell |
60,600
-11,500
| -16% | -$944K | ﹤0.01% | 3046 |
|
|
2019
Q1 | $6.35M | Buy |
72,100
+16,300
| +29% | +$1.36M | ﹤0.01% | 2651 |
|
|
2018
Q4 | $3.98M | Buy |
55,800
+14,700
| +36% | +$1.41M | ﹤0.01% | 3112 |
|
|
2018
Q3 | $5.05M | Sell |
41,100
-8,500
| -17% | -$964K | ﹤0.01% | 2991 |
|
|
2018
Q2 | $4.87M | Buy |
49,600
+26,600
| +116% | +$2.38M | ﹤0.01% | 2814 |
|
|
2018
Q1 | $1.91M | Sell |
23,000
-200
| -0.9% | -$16.9K | ﹤0.01% | 3807 |
|
|
2017
Q4 | $1.8M | Sell |
23,200
-1,200
| -5% | -$81.9K | ﹤0.01% | 3785 |
|
|
2017
Q3 | $1.5M | Sell |
24,400
-28,400
| -54% | -$1.5M | ﹤0.01% | 3777 |
|
|
2017
Q2 | $2.43M | Buy |
52,800
+14,200
| +37% | +$689K | ﹤0.01% | 2915 |
|
|
2017
Q1 | $1.67M | Sell |
38,600
-20,700
| -35% | -$887K | ﹤0.01% | 3278 |
|
|
2016
Q4 | $2.29M | Buy |
59,300
+35,200
| +146% | +$1.59M | ﹤0.01% | 2792 |
|
|
2016
Q3 | $1.22M | Sell |
24,100
-7,000
| -23% | -$349K | ﹤0.01% | 3566 |
|
|
2016
Q2 | $1.41M | Sell |
31,100
-28,000
| -47% | -$1.29M | ﹤0.01% | 3134 |
|
|
2016
Q1 | $2.34M | Sell |
59,100
-27,400
| -32% | -$1.09M | ﹤0.01% | 2481 |
|
|
2015
Q4 | $4.89M | Buy |
86,500
+12,400
| +17% | +$630K | 0.01% | 1842 |
|
|
2015
Q3 | $2.95M | Buy |
74,100
+37,600
| +103% | +$1.82M | ﹤0.01% | 2490 |
|
|
2015
Q2 | $1.74M | Sell |
36,500
-1,100
| -3% | -$46.6K | ﹤0.01% | 3215 |
|
|
2015
Q1 | $1.49M | Sell |
37,600
-1,700
| -4% | -$60.8K | ﹤0.01% | 3443 |
|
|
2014
Q4 | $878K | Buy |
39,300
+13,800
| +54% | +$261K | ﹤0.01% | 3918 |
|
|
2014
Q3 | $400K | Buy |
25,500
+7,300
| +40% | +$109K | ﹤0.01% | 4917 |
|
|
2014
Q2 | $270K | Buy |
18,200
+4,500
| +33% | +$63.5K | ﹤0.01% | 5197 |
|
|
2014
Q1 | $221K | Sell |
13,700
-3,000
| -18% | -$51.3K | ﹤0.01% | 5406 |
|
|
2013
Q4 | $156K | Sell |
16,700
-4,200
| -20% | -$41K | ﹤0.01% | 5254 |
|
|
2013
Q3 | $237K | Sell |
20,900
-7,700
| -27% | -$106K | ﹤0.01% | 4600 |
|
|
2013
Q2 | $383K | Buy |
+28,600
| New | +$351K | ﹤0.01% | 4092 |
|
Other funds holding NBIX
VPM
VCM
Citadel Advisors's NBIX Position: Q1 2026 in Review
Citadel Advisors reduced its Neurocrine Biosciences (NBIX) stake by 27% in Q1 2026, selling an estimated $2.88M and leaving 57,968 shares worth $7.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3660.
Citadel Advisors first reported a position in NBIX in Q2 2013 and has held it in 50 quarters since. The position peaked at $346M in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Citadel Advisors held 57,968 shares of Neurocrine Biosciences worth $7.64M as of Q1 2026.
- Citadel Advisors sold 21,743 Neurocrine Biosciences shares in Q1 2026, an estimated $2.88M.
- Neurocrine Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3660 holding.
- Citadel Advisors first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 50 quarters since.
- Citadel Advisors's Neurocrine Biosciences position peaked at $346M in Q4 2024.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.